Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 7/20 | 0.38 |
| ▸ | DRD3 | P35462 | 6/20 | 0.38 |
| ▸ | DRD4 | P21917 | 5/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11300057 | 1.00 | POLB (0.42) | POLBL3MBTL1DRD2DRD3DRD4 | |
| SCHEMBL11219569 | 0.94 | POLB (0.37) | POLBL3MBTL1DRD2DRD3DRD4 | |
| SCHEMBL8799867 | 0.82 | CHRNB2 (0.37) | DRD2DRD3DRD4CA12CA1 | |
| SCHEMBL2573666 | 0.80 | POLB (0.47) | POLBL3MBTL1SPHK2SPHK1 | |
| SCHEMBL5804458 | 0.80 | DRD2 (0.38) | DRD2DRD3DRD4CA12CA1 | |
| SCHEMBL8514098 | 0.80 | POLB (0.47) | POLBL3MBTL1SPHK2SPHK1 | |
| SCHEMBL11445454 | 0.80 | DRD2 (0.36) | DRD2DRD3DRD4CA12CA1 | |
| SCHEMBL11251940 | 0.80 | DRD2 (0.36) | DRD2DRD3DRD4CA12CA1 | |
| SCHEMBL9154751 | 0.80 | DRD2 (0.38) | DRD2DRD3DRD4CA12CA1 | |
| SCHEMBL7372904 | 0.77 | DRD2 (0.36) | DRD2DRD3DRD4CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
| CN-117500799-A | Substituted fused azines as KRAS G12D inhibitors | 伊莱利利公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230257374-A1 | NOVEL KRAS G12C PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | INNOVENT BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| WO-2022261154-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261154-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-12-15 | — | — | WO | disclosed |
| US-5948793-A | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release | ABBOTT LABORATORIES (US) | 1999-09-07 | — | — | US | disclosed |
| US-5914328-A | CONTROL DOPAMINE RELEASE, ACTIVATE CHOLINERGIC CHANNELS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | KRAS, NRAS, TP53 | POLB 2327/4885L3MBTL1 2974/4885DRD2 893/4885 |
| US-20230257374-A1 | NOVEL KRAS G12C PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | KRAS, NRAS, RASGRP1 | POLB 2660/4885L3MBTL1 4464/4885DRD2 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.